MedTrace Logo

Concentrations of Maraviroc in the Semen of HIV-Infected Men

NCT01009034 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2014-09-09

Study results available
· View outcomes & findings →

Summary

The objective of this study is to determine if concentrations of maraviroc in semen exceed the 50% and 95% inhibitory concentrations of HIV during the dose interval.

The secondary objective is to determine the extent of maraviroc penetration into semen by obtaining semen to plasma ratios across the dosing interval, to determine the area under the concentration time curve of maraviroc in semen, and to determine the variability in the penetration of maraviroc into the seminal compartment over the maraviroc dosing period.

Conditions

  • Maraviroc Concentrations in Semen

Interventions

OTHER

Measuring semen samples

Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of maraviroc in semen, the variability in the penetration of maraviroc into the seminal compartment over the raltegravir dosing period.

Sponsors & Collaborators

  • Canadian Immunodeficiency Research Collaborative

    lead OTHER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-12-31
Completion
2012-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01009034 on ClinicalTrials.gov